The coronavirus pandemic has not only affected the economies of different countries as well as industries around the world, but it has also affected the mental and emotional health of millions of individuals globally.
Field Trip Health, one of the biggest providers of psychedelic therapies globally, recently conducted a survey in the United States focused on both emotional and mental health. The company’s aim was to find out how open-minded respondents were towards including psychedelics into their treatment plans. The survey’s results report that more than 8 out of every 10 individuals who responded experienced at least one symptom of depression. This differs from results of more than 75% of the respondents, who stated that their mental health was OK or better, showing a disparity between self-perception and a potential lack of understanding of mental health metrics.
The survey highlights that only 10% of individuals aged 65 and above self-reported symptoms of depression, which is a small number in comparison with the majority group, which was made up of individuals aged 18 to 24 and had the highest results. In addition to this, one in every four respondents reported that they had thought of harming themselves or had felt that they would be better off dead.
The survey also found that a majority of the participants had turned to coping mechanisms such as drugs to help them deal with negative emotions and thoughts. Other coping mechanisms mentioned included gambling, overeating, porn and alcohol. Reports show that the consumption of alcohol increased by more than 30% since the onset of the pandemic. Despite this, however, more than 40% of the survey participants also relied on the support of a counselor, therapist or mental health professional.
The findings also show that, in comparison with men, women reported worse negative mental health outcomes throughout the pandemic and were more likely to show negative mental health states. This was in addition to bearing the brunt of the negative effects on their financial and professional security. The study results also noted that while 70% of respondents had never used psychedelic substances, more than 30% revealed that they supported the use of these substances in psychedelic-assisted therapies, with more than 20% revealing that they’d like to learn more about psychedelics. Furthermore, 24% of respondents were open to trying psychedelic-assisted therapies.
Currently, more states across the country are moving to legalize the use of these substances in treating various mental conditions. The survey results propose that many may seek these alternative treatment options once they become available.
As public awareness about the medicinal value of psychedelics grows, sector players such as XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are likely to ramp up their R&D efforts in order to meet the demand when these treatments are finally approved and made available to the general public.
NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.